CA-CHARGEPOINT
19.6.2024 09:01:31 CEST | Business Wire | Press release
ChargePoint (NYSE: CHPT), a leading provider of networked charging solutions for electric vehicles (EVs), today announced a suite of updates and additions to its be.ENERGISED platform, a leading European software solution for the management of charging networks and e-mobility services at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240619736580/en/
(Photo: Business Wire)
be.ENERGISED now manages over 900 models of charging stations from more than 100 manufacturers. New features, offerings and enhancements include:
- The first payment terminal to meet the new OCPI v2.2.1 Direct Payment Module industry standards and comply with the recently instated AFIR (Alternative Fuel Infrastructure Regulation).
- eMobility Service Providers (eMSPs) can use the solutions’ roaming network to give their drivers selected access to more than 750,000 stations across the whole of Europe. Charge Point Operators (CPOs) can easily make their stations available to the public and all drivers on the major eMSPs via be.ENERGISED COMMUNITY roaming agreements in just a few clicks of a mouse.
- In addition, the CP6000 - ChargePoint’s most flexible and serviceable global AC EV charging solution - is available from this week on the be.ENERGISED platform to select customers. The CP6000 is designed for scalability, flexibility, and reliability, offering reliable AC charging for 1 or 3 phase power at an adaptable output of 3.7 to 22kw per port.
ChargePoint’s be.ENERGISED platform boasts consolidated services for CPOs and eMSPs, including VAT handling, automated invoicing, streamlining financial operations for multinational charging providers. With over 85,000 charging ports and 30 million charging sessions per month, be.ENERGISED’s scale and experience are unparalleled in the industry. The software offers an end-to-end solution capable of addressing every aspect of the charging process, providing unmatched flexibility and modularity to cater to all use cases.
The EV charging landscape is rapidly evolving, with CPOs and eMSPs becoming far more sophisticated, often relying on many makes of chargers and hundreds of software integrations with partners. As their expertise deepens, so do their needs, transforming from initial solutions into intricate networks which require robust protection and management. This shift signifies a move from the early days of greenfield projects to the current “brownfield” environment, where existing charger investments must be futureproofed alongside the implementation of new infrastructure. Though new chargers are constantly being brought online, ensuring a reliable network requires legacy hardware running just as well as the newest installations. All of this underscores the need for a well-rounded, adaptable software solution such as be.ENERGISED.
“A new set of market demands necessitates even the most advanced charger management platforms to deliver innovative features for the future,” said Andreas Blin, Director for Service Provision at ChargePoint. “A leader in the market for more than a decade, be.ENERGISED meets the challenges charging businesses face, ensuring that both new and existing infrastructure can excel in an ever more dynamic environment.”
Since acquiring be.ENERGISED three years ago, ChargePoint has continued to foster and develop the product to ensure market leadership while delivering bespoke solutions for international customers. be.ENERGISED is now the most flexible and comprehensive solution on the market, and one built for the future without forgetting about the past.
To learn more about ChargePoint’s be.ENERGISED platform, please click here or visit the ChargePoint stand B6.111Hall B6 at the Power2Drive charging infrastructure exposition in Munich held June 19-21st.
About ChargePoint Holdings, Inc.
ChargePoint is creating a new fuelling network to move people and goods on electricity. Since 2007, ChargePoint has been committed to making it easy for businesses and drivers to go electric with one of the largest EV charging networks and a comprehensive portfolio of charging solutions. The ChargePoint cloud subscription platform and software-defined charging hardware are designed to include options for every charging scenario from home and multifamily to workplace, parking, hospitality, retail, and transport fleets of all types. Today, one ChargePoint account provides access to hundreds-of-thousands of places to charge in North America and Europe. For more information, visit the ChargePoint pressroom, the ChargePoint Investor Relations site, or contact the ChargePoint North American or European press office or Investor Relations.
CHPT-IR
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619736580/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
